U.S. markets close in 48 minutes

Novartis AG (NVS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
84.60+1.45 (+1.74%)
As of 3:12PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close83.15
Bid84.68 x 800
Ask84.69 x 900
Day's Range84.09 - 84.96
52 Week Range77.04 - 98.52
Avg. Volume1,930,867
Market Cap189.228B
Beta (5Y Monthly)0.55
PE Ratio (TTM)21.43
EPS (TTM)3.95
Earnings DateN/A
Forward Dividend & Yield3.20 (3.85%)
Ex-Dividend DateMar 04, 2021
1y Target Est104.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novartis AG
    Analyst Report: Novartis AGNovartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • GlobeNewswire

    Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

    Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care Facilitated by Novartis, Invisible Nation will aim to reduce and ultimately prevent many of the 15 million1 ASCVD deaths each year and dramatically lower what is estimated to become $1 trillion in annual CV disease care cost by 20302Network members will engage policymakers, healthcare syste

  • Motley Fool

    3 No-Brainer Stocks to Buy Right Now

    These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term.

  • American City Business Journals

    Scientist behind Vertex CF drugs launches new startup with Atlas Venture

    Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.